Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5015978 | 0.97 | LMNA (0.40) | LMNADPP4OPRM1OPRD1SLC6A3 | |
| SCHEMBL25530903 | 0.97 | LMNA (0.40) | LMNADPP4OPRM1OPRD1SLC6A3 | |
| SCHEMBL284393 | 0.97 | LMNA (0.40) | LMNADPP4OPRM1OPRD1SLC6A3 | |
| Hydrochloric Acid SCHEMBL25215294 | 0.95 | LMNA (0.39) | LMNADPP4OPRM1OPRD1SLC6A3 | |
| Hydrochloric Acid SCHEMBL19926062 | 0.95 | LMNA (0.39) | LMNADPP4OPRM1OPRD1SLC6A3 | |
| SCHEMBL5022562 | 0.94 | — | — | |
| Hydrochloric Acid SCHEMBL34473465 | 0.92 | LMNA (0.32) | LMNA | |
| SCHEMBL2843814 | 0.88 | — | — | |
| Hydrochloric Acid SCHEMBL34474173 | 0.86 | OPRM1 (0.31) | OPRM1 | |
| Trifluoroacetic Acid SCHEMBL3752134 | 0.80 | LMNA (0.38) | LMNAOPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200308155-A1 | Substituted Ureas and Methods of Making and Using Same | MEBIAS DISCOVERY, INC. | 2020-10-01 | — | — | US | claimed |
| EP-3506983-A1 | SUBSTITUTED UREAS AND METHODS OF MAKING AND USING SAME | Mebias Discovery LLC (US) | 2019-07-10 | — | — | EP | claimed |
| US-20190194178-A1 | SUBSTITUTED UREAS AND METHODS OF MAKING AND USING SAME | MEBIAS DISCOVERY LLC | 2019-06-27 | — | — | US | claimed |
| CN-109843379-A | Substituted ureas and methods of making and using the same | 梅比斯发现公司 | 2019-06-04 | — | — | CN | claimed |
| WO-2018045229-A1 | SUBSTITUTED UREAS AND METHODS OF MAKING AND USING SAME | MEBIAS DISCOVERY LLC (US) | 2018-03-08 | — | — | WO | claimed |
| CN-115667233-B | Novel 2-arylthiazole derivative or salt thereof, process for preparing the same and pharmaceutical composition comprising the same | 六合医药科技有限公司 | 2024-05-24 | — | — | CN | disclosed |
| US-20230339976-A1 | KRAS G12D INHIBITORS | Mirati Therapeutics, Inc. | 2023-10-26 | — | — | US | disclosed |
| EP-4192585-A1 | KRAS G12D INHIBITORS | Mirati Therapeutics, Inc. (US) | 2023-06-14 | — | — | EP | disclosed |
| CN-109843379-B | Substituted ureas and methods of making and using the same | 梅比斯发现公司 | 2022-12-30 | — | — | CN | disclosed |
| WO-2022031678-A1 | KRAS G12D INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-02-10 | — | — | WO | disclosed |
| US-11198685-B2 | Substituted ureas and methods of making and using same | MEBIAS DISCOVERY, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| US-20200308155-A1 | Substituted Ureas and Methods of Making and Using Same | MEBIAS DISCOVERY, INC. | 2020-10-01 | — | — | US | disclosed |
| US-20040242685-A1 | N-[(1-dimethylaminocycloalkyl)methyl]benzamide derivatives | N.V. ORGANON (NL) | 2004-12-02 | — | — | US | disclosed |
| EP-1438046-A4 | THIAZOLE BENZAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING CELL PROLIFERATION, AND METHODS FOR THEIR USE | AGOURON PHARMA (US) | 2004-10-20 | — | — | EP | disclosed |
| EP-1438046-A2 | THIAZOLE BENZAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING CELL PROLIFERATION, AND METHODS FOR THEIR USE | AGOURON PHARMACEUTICALS, INC. (US) | 2004-07-21 | — | — | EP | disclosed |
| EP-1419138-A1 | N- (1-DIMETHYLAMINOCYCLOALKYL)METHYL]BENZAMIDE DERIVATIVES | Akzo Nobel (NL) | 2004-05-19 | — | — | EP | disclosed |
| US-6720346-B2 | (4-AMINOTHIAZOL-2-YLAMINO)-BENZAMIDE COMPOUNDS; PROTEIN KINASE INHIBITORS; CANCER; AUTOIMMUNE, VIRAL, FUNGAL, NEURODEGENERATIVE, AND CARDIOVASCULAR DISORDERS | AGOURON PHARMACEUTICALS, INC. | 2004-04-13 | — | — | US | disclosed |
| US-20030225147-A1 | Thiazole benzamide derivatives and pharmaceutical compositions for inhibiting cell proliferation, and methods for their use | AGOURON PHARMACEUTICALS INC. | 2003-12-04 | — | — | US | disclosed |
| WO-2003010132-A1 | N-[(1-DIMETHYLAMINOCYCLOALKYL)METHYL]BENZAMIDE DERIVATIVES | AKZO NOBEL N.V. (NL) | 2003-02-06 | — | — | WO | disclosed |
| WO-2003004467-A2 | THIAZOLE BENZAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING CELL PROLIFERATION, AND METHODS FOR THEIR USE | AGOURON PHARMACEUTICALS, INC. (US) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225147-A1 | Thiazole benzamide derivatives and pharmaceutical compositions for inhibiting cell proliferation, and methods for their use | TK1, MKI67, CDKN1A | LMNA 3416/4885DPP4 584/4885OPRM1 4116/4885 |
| US-20190194178-A1 | SUBSTITUTED UREAS AND METHODS OF MAKING AND USING SAME | UMPS, METTL3, UTS2R | LMNA 1718/4885DPP4 2874/4885OPRM1 178/4885 |
| US-11198685-B2 | Substituted ureas and methods of making and using same | UMPS, METTL3, UTS2R | LMNA 1718/4885DPP4 2874/4885OPRM1 178/4885 |
| US-20200308155-A1 | Substituted Ureas and Methods of Making and Using Same | UMPS, METTL3, UTS2R | LMNA 1718/4885DPP4 2874/4885OPRM1 178/4885 |
| US-20040242685-A1 | N-[(1-dimethylaminocycloalkyl)methyl]benzamide derivatives | SLC1A2, SLC6A1, KCNT2 | LMNA 3106/4885DPP4 671/4885OPRM1 351/4885 |
| US-20230339976-A1 | KRAS G12D INHIBITORS | KRAS, NRAS, HRAS | LMNA 4069/4885DPP4 2736/4885OPRM1 4767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.